- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02680717
Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Morphea, also known as localized scleroderma, is a rare autoimmune fibrosing disorder that affects children and adults. Morphea causes significant morbidity through atrophy and fibrosis of the skin and underlying structures. Treatment can halt the progression of disease but cannot reverse disease damage, leaving children with disfiguring scars and sometimes functional impairment. Consequently, it is of extreme importance to intervene early in the disease course with effective therapies to limit morbidity.
Circumscribed morphea is the second most common subtype in children, comprising approximately 1/3 of pediatric morphea cases. It is a disfiguring disease that can cause pain and pruritus. There are no FDA-approved treatments and no consensus exists on the ideal therapy for circumscribed morphea, either in adults or children. Most physicians use topical medications for circumscribed morphea yet there is little evidence to support these therapies. Topical immune modulators such as tacrolimus, imiquimod, and calcipotriene have been investigated in small studies, though these trials were limited by very small sample sizes of 9-19 patients and lack of a control in most. Surveys have demonstrated that topical steroids are the most commonly prescribed medication, even though the only evidence to support their use comes from case reports. With insufficient evidence regarding topical therapies, providers have no guidance when making treatment decisions, practice patterns vary widely even amongst pediatric dermatologists, and children continue with preventable scars.
The investigators specific aim is to identify effective topical therapy for circumscribed morphea. The investigators will utilize a comparative cohort study design to evaluate the comparative effectiveness of three topical medications: clobetasol ointment, calcipotriene ointment, and tacrolimus 0.1% ointment. The investigators will enroll subjects at CHW and other institutions to achieve the study enrollment necessary to power this study.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- presence of at least 1 active lesion of morphea on the neck, trunk, or extremities with no prior treatment to that lesion for at least 4 weeks
Exclusion Criteria:
- children receiving phototherapy or systemic therapy for their morphea
- children with linear or generalized morphea
- lesions on the face
- greater than 3% body surface area involvement
- open or ulcerated skin within morphea lesions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment 1
Calcipotriene 0.005% ointment
|
ointment, twice daily
|
Active Comparator: Treatment 2
Clobetasol 0.05% ointment
|
ointment, twice daily (alternating weeks)
|
Active Comparator: Treatment 3
Tacrolimus 0.1% ointment
|
ointment, 0.1%, twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analog Scale
Time Frame: 2 months
|
This is a 100 mm scale with 3 anchors; each 5 mm of the scale is equivalent to 10% change.
|
2 months
|
Visual Analog Scale
Time Frame: 4 months
|
This is a 100 mm scale with 3 anchors; each 5 mm of the scale is equivalent to 10% change.
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yvonne Chiu, MD, Medical College of Wisconsin
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Connective Tissue Diseases
- Scleroderma, Localized
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Calcineurin Inhibitors
- Calcipotriene
- Tacrolimus
- Clobetasol
Other Study ID Numbers
- 730382-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scleroderma
-
University of Texas Southwestern Medical CenterRecruitingScleroderma, Localized | Morphea | Frontal Linear Scleroderma en Coup de Sabre | Scleroderma, Circumscribed | Scleroderma, LinearUnited States
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Gilead SciencesCompletedDiffuse Scleroderma | Limited SclerodermaAustralia
-
Mastelli S.r.lSintesi Research SrlTerminatedScleroderma DiseaseItaly
-
Lawson Health Research InstituteNovartis PharmaceuticalsTerminated
-
BiocadRecruitingSystemic SclerodermaRussian Federation
-
Rennes University HospitalCompleted
-
Castle Creek Biosciences, LLC.TerminatedScleroderma, Localized | Morphea | SclerodermaUnited States
-
Assistance Publique - Hôpitaux de ParisActelionCompleted
-
University Hospital, LilleRecruiting
Clinical Trials on Calcipotriene
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
Mayne Pharma International Pty LtdGlaxoSmithKlineCompleted
-
Northwestern UniversityTerminated
-
Polichem S.A.Almirall, S.A.Withdrawn
-
Deltanoid PharmaceuticalsCompletedPlaque-type PsoriasisUnited States
-
Mayne Pharma International Pty LtdGlaxoSmithKlineCompleted
-
Massachusetts General HospitalTerminated
-
Rabin Medical CenterUnknown
-
Maruho Co., Ltd.CompletedPlaque PsoriasisUnited States
-
Sienna BiopharmaceuticalsCompletedPsoriasis | PruritusUnited States, Canada